Skip to main content
SpringerLink
Log in

In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

S 9788 is a novel triazinoaminopiperidine derivative which does not belong to any of the classes of compounds known to reverse multidrug resistance (MDR). S 9788 was far more potent than verapamil (VRP) in reversing resistance to adriamycin (ADR) in the ADR-selected murine leukaemia cell lines P388/ADR-1 and P388/ADR-10, and the human chronic myelogenous leukaemia K562/R. Fold reversion with S 9788 (5μM was, respectively, 3.5, 5.4 and 11.3 times greater than that with VRP (5μM). S 9788 was also a more potent reversant of ADR resistance in the intrinsically resistant human colon adenocarcinoma COLO 320DM (2.3 fold), and of vincristine (VCR) resistance in the human MDR1 gene-transfected squamous lung carcinoma line S1/tMDR1 (5.6 fold). The activity of S 9788 depended on both the MDR cell line and the cytotoxic agent. S 9788 (50–100 mg/kg/d) administered IP once a day on days 1–4 resulted in a dose-dependent increase in the chemotherapeutic effect of VCR (0.25 mg/kg/d) in P388/VCR-bearing mice and ADR (4 mg/kg/d) in P388/ADR-bearing mice. Increases in antitumor activity were (% T/C) of +20–34% in the P388/ADR model and +50–78% in the P388/VCR model with respect to cytotoxic agent treatment alone. S 9788 appeared to be devoid of toxicity at its effective doses. The mechanism of action of S 9788 is unknown but S 9788 (0.5–10μM) induced a dose-dependent increase in ADR accumulation in KB-Al cells and compared to verapamil its effect was twice as active and approximately seven times more potent. We conclude that S 9788 is a novel agent capable of reversing MDRin vitro andin vivo, and whose pharmacological profile warrants its selection as a candidate drug for eventual assessment in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human cancers, J Natl Cancer Inst 81:116–124, 1989

    PubMed  Google Scholar 

  2. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, Kaye SB: P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 62:758–761, 1990

    PubMed  Google Scholar 

  3. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160–7164, 1990

    PubMed  Google Scholar 

  4. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS: Prediction of doxorubicin resistancein vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696–701, 1989

    PubMed  Google Scholar 

  5. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1288, 1983

    PubMed  Google Scholar 

  6. Ueda K, Clark DP, Chen C, Roninson IB, Gottesman MM, Pastan I: The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262(2):505–508, 1987

    PubMed  Google Scholar 

  7. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483, 1973

    PubMed  Google Scholar 

  8. Inaba M, Kobayashi H, Sakurai Y, Johnson RK: Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukaemia. Cancer Res 39:2200–2203, 1979

    PubMed  Google Scholar 

  9. Gros P, Neriah YB, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728–731, 1986

    PubMed  Google Scholar 

  10. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004–3008, 1987

    PubMed  Google Scholar 

  11. Choi K, Chen C, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug resistant cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53:519–529, 1988

    PubMed  Google Scholar 

  12. Tsuruo T: Reversal of multidrug resistance by calcium channel blockers and other agents. In Roninson IB (ed.) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells, Plenum Publishing Corporation, New York, 1989, pp 349–365

    Google Scholar 

  13. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacological Reviews 42(3):155–199, 1990

    PubMed  Google Scholar 

  14. Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y: Enhancement of vincristine and adriamycin induced cytotoxicity by verapamil in P388 leukaemia and its resistant sublines to vincristine and adriamycin. Biochem Pharmacol 31:3138–3140, 1982

    PubMed  Google Scholar 

  15. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Increased accumulation of vincristine and adriamycin in drug-resistant tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733, 1982

    PubMed  Google Scholar 

  16. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukaemiain vivo andin vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972, 1981

    PubMed  Google Scholar 

  17. Slater LM, Sweet P, Stupecky M, Wetzel MN, Gupta S: Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–238, 1986

    PubMed  Google Scholar 

  18. Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T: Circumvention of multidrug resistance by a newly synthesised quinoline derivative, MS-073. Cancer Res 51:2420–2424, 1991

    PubMed  Google Scholar 

  19. Shinoda H, Inaba M, Tsuruo T:In vivo circumvention of vincristine resistance in mice with P388 leukaemia using a novel compound, AHC-52. Cancer Res 49:1722–1726, 1989

    PubMed  Google Scholar 

  20. Presant CA, Kennedy PS, Wiseman C, Gala K, Bouzaglou A, Wyres M, Naessig V: Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wiltshire Oncology Medical Group Pilot phase I–II Study. Am J Clin Oncol 9(4):355–357, 1986

    PubMed  Google Scholar 

  21. Dalton WS, Grogan TM, Meltzer PS, Schaper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7(4):415–424, 1989

    PubMed  Google Scholar 

  22. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose-verapamil. J Clin Oncol 9(1): 17–24, 1991

    PubMed  Google Scholar 

  23. Reizenstein P: Can verapamil induce second response in patients refractory to vincristine? Anticancer Res 10:955–958, 1990

    PubMed  Google Scholar 

  24. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE: Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83(2): 105–110, 1991

    PubMed  Google Scholar 

  25. Cano-Gauci DF, Riordan JR: Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 36:2115–2123, 1987

    PubMed  Google Scholar 

  26. Warr JR, Brewer F, Anderson M, Fergusson J: Verapamil hypersensitivity of vincristine resistant chinese hamster ovary cell lines. Cell Biol Int Rep 10:389–399, 1986

    PubMed  Google Scholar 

  27. Twentyman PR, Fox NE, Bleehen NM: Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium blocker verapamil. Int J Radiat Oncol Biol Phys 12:1355–1358, 1986

    PubMed  Google Scholar 

  28. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726, 1991

    PubMed  Google Scholar 

  29. De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F: Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukaemia cells. Mol Pharmacol 37:11–16, 1990

    PubMed  Google Scholar 

  30. Slovak ML, Hoeltge GA, Dalton WS, Trent JM: Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48:2793–2797, 1988

    PubMed  Google Scholar 

  31. Slapak CA, Daniel JC, Levy SB: Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res 50:7895–7901, 1990

    PubMed  Google Scholar 

  32. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Graver L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695–698, 1989

    PubMed  Google Scholar 

  33. Arceci RJ, Croop JM, Horwitz SB, Housman D: The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 85:4350–5354, 1988

    PubMed  Google Scholar 

  34. Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukaemia cells. Molecular Pharmacol 33:454–462, 1988

    Google Scholar 

  35. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen W, Joenje H: Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49:2988–2993, 1989

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division de Cancérologie expérimentale, Institut de Recherches Servier, 11 rue des Moulineaux, 92150, Suresnes, France

    Alain Pierré, Theresa A. Dunn, Laurence Kraus-Berthier, Stéphane Léonce, Dominique Saint-Dizier, Gilbert Régnier, Alain Dhainaut, Maryse Berlion, Jean-Pierre Bizzari & Ghanem Atassi

  2. Division Thérapeutique Cancérologie, Institut de Recherches Internationales Servier, 6 Place des Pléiades, 92415, Courbevoie Cedex, France

    Alain Pierré, Theresa A. Dunn, Laurence Kraus-Berthier, Stéphane Léonce, Dominique Saint-Dizier, Gilbert Régnier, Alain Dhainaut, Maryse Berlion, Jean-Pierre Bizzari & Ghanem Atassi

Authors
  1. Alain Pierré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theresa A. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Kraus-Berthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stéphane Léonce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dominique Saint-Dizier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gilbert Régnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alain Dhainaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maryse Berlion
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Pierre Bizzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ghanem Atassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pierré, A., Dunn, T.A., Kraus-Berthier, L. et al. In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 10, 137–148 (1992). https://doi.org/10.1007/BF00877238

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877238

Key words

Search

Navigation